S/GSK1349572 (Dolutegravir)

Catalog No. A11068

S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones.
  • Lea El Khoury, .et al. Spectrometric and computational studies of the binding of HIV-1 integrase inhibitors to viral DNA extremities, PeerJ Preprints, 2019, 7:e27833v1
Catalog Num A11068
M. Wt 419.4
Formula C20H19F2N3O5
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1051375-16-6
Synonyms Dolutegravir, GSK-1349572
SMILES C[[email protected]@H]1CCO[[email protected]@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones.
Targets
HIV integrase (Cell-free assay)
2.7 nM
In vitro DMSO 83 mg/mL heating (197.91 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 23.84 mL 119.22 mL 238.44 mL
0.5 mM 4.77 mL 23.84 mL 47.69 mL
1 mM 2.38 mL 11.92 mL 23.84 mL
5 mM 0.48 mL 2.38 mL 4.77 mL

*The above data is based on the productmolecular weight 419.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.